Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features

NARecruitingINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Pancreatic SteatosisPancreatic Cyst
Interventions
DIAGNOSTIC_TEST

MRI for pancreatic fat and liver fat quantitation

MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2\* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.

Trial Locations (1)

Unknown

RECRUITING

Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT05334836 - Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features | Biotech Hunter | Biotech Hunter